This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
There has been substantial interest in a possible increased risk of developing severe coronavirus disease 2019 (COVID-19) in patients with autoimmune diseases.1 Early observations in people with multiple sclerosis (MS) did not uniformly confirm such an increase.2,3 However, several observations point toward a different risk profile for severe COVID-19 with the use of specific disease-modifying therapies (DMTs) in people with MS.3,4 In addition, attenuated humoral responses after both COVID-19 infection5,6 and vaccination have been reported for different DMTs.1,7,8 The exact magnitude of the increased risk of a more complicated COVID-19 disease course in MS subgroups on different DMTs still has to be established. More knowledge about the specific risk profiles for each DMT will be very important in counseling patients. It is important to take COVID-19 severity proportionally into account for the risk-benefit evaluation at treatment start and switch in MS. Large cohort studies to confirm the relationship between DMTs and COVID-19 severity have remained elusive until now.
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
See page 891
- © 2021 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
